Pfizer Signs MOU With Wuhan To Establish First R&D Center In Midwest China; Ranks Number One In China
This article was originally published in PharmAsia News
SHANGHAI - Pfizer is expanding its presence in central and Western China, having signed a memorandum of understanding with Wuhan National Bioindustry Base Construction and Management Office Nov. 25 to establish a new R&D site in the National Bioindustry Base Biolake in Wuhan, the province capital of Hubei
You may also be interested in...
One of the largest industrial estates in Southeast Asia is in Cikarang, West Java, Indonesia. It and dozens of clusters are fueling a realignment of the global pharmaceutical industry and pushing up real estate prices across Asia.
Western-style perks are increasingly being offered to local staff by major pharmaceutical companies seeking to expand quickly in China, according to a recent report.
SHANGHAI - Shrinking margins are adding pressure to contract research organizations in the U.S., and on the other side of the globe, CROs in China are facing the same problem, due to higher labor costs and appreciation of the RMB. Led by WuXi AppTec Inc., the largest Chinese CRO, local CROs are expanding services by entering into new partnering models with multinational clients and preparing for increasing domestic demands